Ann: Starpharma commences phase 1/2 DEP irinotecan trial, page-3

This is nice, but I won’t get excited until Starpharma announces it’s COMPLETED a phase II trial and demonstrated the efficacy of its DEP platform in cancer. This is what the main value of the company rests on, and we will remain in a holding pattern until we see the results from the DEP-docetaxel trial proving that it actually decreases side-effects while being equally or more efficacious than standard docetaxel.

This is where SPL should be focussing their attention, putting more money into more trial sites if necessary, to complete the prof-of-principal phase II trial for at least one DEP-anti cancer compound.